My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

77.27 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)

October 11, 2022

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

October 07, 2022

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Earnings Perspective: Return On Capital Employed ↗

August 25, 2022

According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 25, 2022

Via Benzinga

BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial ↗

August 18, 2022

Via Benzinga

BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate ↗

July 26, 2022

Via Benzinga

BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease ↗

June 22, 2022

Via Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate ↗

May 26, 2022

Via Benzinga

Where BridgeBio Pharma Stands With Analysts ↗

May 06, 2022

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off ↗

August 18, 2022

BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by...

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 10, 2022

Via Benzinga

BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative' ↗

May 05, 2022

Via Benzinga

BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial ↗

April 04, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO)

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 03, 2022

Via Benzinga

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗

July 26, 2022

Via Benzinga

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

July 26, 2022

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reveals Early Positive Data For Canavan Disease ↗

June 22, 2022

BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.

Via Benzinga

BridgeBio Pharma's Return On Capital Employed Insights ↗

May 31, 2022

Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

6 Analysts Have This to Say About BridgeBio Pharma ↗

May 24, 2022

Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder ↗

May 20, 2022

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology ↗

May 12, 2022

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data ↗

March 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

What 6 Analyst Ratings Have To Say About BridgeBio Pharma ↗

March 16, 2022

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.